AFP EXTRA
- Code
- 900.0125
- Name
- AFP EXTRA
- Category
- None
- Department
- Send-Out
- Start Date
- Expiration Date
- Synonyms
- Prenatal Risk Triple Marker, Triple Marker
- CPT Codes
- 82105; 82677; 84702
- Site
- SBMF
- Reference Test
- 30080
Specimen Information
- Type
Gold, SST
- Volume
4.0 ml
- Transport Info
Refrigerated
- Fasting Required?
- False
- Patient Instructions
Specimen must be collected between 15th and 22nd week of gestation for a complete risk analysis (optimal time is 16-18 weeks)
Collect sample prior to amniocentesis
Complete a Prenatal Risk Information Sheet and send with sample (requires following items of information):
– Estimated due date by LMP
– Mother’s weight in pounds
– Mother’s status of insulin-dependent diabetes
– # of fetuses in current pregnancy (1 or 2)
Note: Pregnancies with more than 2 fetuses cannot be assessed
– Mother’s race
– Mother’s exact date of birth (mm/dd/yyyy)
– Is this a repeat sample? (yes/no)- Reference Range
Neural Tube Defect (NTD) Risk Screen: Negative
Down Syndrome (DS) Risk Screen: Negative- Methodology
Chemiluminescence Immunoassay (CLIA)
Clinical Significance
Used to screen for fetal risk of open Neural Tube Defects (NTD) and Down Syndrome (DS)
This procedure includes performing three (3) tests, alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and unconjugated/free estriol (uE3), on serum specimens from expectant mothers at the gestational age between 15 and 22 weeks. Based on the results of these tests and maternal age at the expected date of delivery (EDD), risk factors for bearing a child with open neural tube defects (NTD) and/or Down Syndrome (DS) are calculated.